Chemokine Therapeutics Corp.

VANCOUVER, March 24 /PRNewswire-FirstCall/ - Chemokine Therapeutics Corp. (the Company) (TSX: CTI - News; OTCBB: CHKT - News), a biotechnology company developing drugs in the field of chemokines, today announced that investigators at the National Cancer Institute (NCI) have demonstrated the potential pathways whereby the Company's anti-cancer compound CTCE-9908 reduces metastatic nodules in a model of osteosarcoma (a type of bone cancer). CTCE-9908 is designed to inhibit the growth and spread of certain common cancers with the potential for use with existing therapies (chemotherapy, surgery, and radiation) to improve treatment outcomes.

Comment - This announcement coupled with the recent announcements regarding institutional financing says, "PUT THIS ONE ON YOUR RADAR." I love that they are working with NCI on this project.